iPSC Therapy for Parkinson's Disease

Migration, Crosslink

📖

iPSC Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ipsc-therapy-parkinson

📖 Wiki Page

therapeutic1816 wordssynced 2026-04-02

iPSC Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iPSC Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Human embryonic stem cell (hESC)-derived dopaminergic progenitors</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Stereotactic injection into the striatum</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Phase 1 clinical trial completed</td>
</tr>
<tr>
<td class="label">Clinicaltrials.gov</td>
<td>NCT04802733</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Cell Source</td>
<td>Autologous (patient-derived) and allogeneic iPSCs</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>iPSC-derived dopaminergic progenitors</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Stereotactic injection into the striatum</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Phase 1/2 clinical trials</td>
</tr>
<tr>
<td class="label">Institution</td>
<td>Kyoto University Hospital</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">Day 1-6</td>
<td>6 days</td>
</tr>
<tr>
<td class="label">Day 7-12</td>
<td>6 days</td>
</tr>
<tr>
<td class="label">Day 13-18</td>
<td>6 days</td>
</tr>
<tr>
<td c

...

iPSC Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iPSC Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Human embryonic stem cell (hESC)-derived dopaminergic progenitors</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Stereotactic injection into the striatum</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Phase 1 clinical trial completed</td>
</tr>
<tr>
<td class="label">Clinicaltrials.gov</td>
<td>NCT04802733</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Cell Source</td>
<td>Autologous (patient-derived) and allogeneic iPSCs</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>iPSC-derived dopaminergic progenitors</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Stereotactic injection into the striatum</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Phase 1/2 clinical trials</td>
</tr>
<tr>
<td class="label">Institution</td>
<td>Kyoto University Hospital</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">Day 1-6</td>
<td>6 days</td>
</tr>
<tr>
<td class="label">Day 7-12</td>
<td>6 days</td>
</tr>
<tr>
<td class="label">Day 13-18</td>
<td>6 days</td>
</tr>
<tr>
<td class="label">Day 19-25</td>
<td>7 days</td>
</tr>
<tr>
<td class="label">Day 26+</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Method</td>
<td>What It Measures</td>
</tr>
<tr>
<td class="label">MRI</td>
<td>Cell survival, location</td>
</tr>
<tr>
<td class="label">PET ([¹⁸F]FDOPA)</td>
<td>Dopamine synthesis</td>
</tr>
<tr>
<td class="label">SPECT ([¹²³I]FP-CIT)</td>
<td>Dopamine transporters</td>
</tr>
<tr>
<td class="label">CSF biomarkers</td>
<td>Neurotrophic factors</td>
</tr>
<tr>
<td class="label">Clinical scales</td>
<td>Motor function</td>
</tr>
</table>

Induced pluripotent stem cell (iPSC) therapy represents one of the most promising approaches in regenerative medicine for Parkinson's disease (PD). This cell replacement therapy aims to restore dopaminergic neuron function by transplanting iPSC-derived dopaminergic progenitors into the brains of patients with Parkinson's disease[@takahashi2023]. Unlike symptomatic treatments that only manage motor symptoms, iPSC therapy has the potential to address the underlying neurodegeneration and potentially modify disease progression.

Parkinson's disease is characterized by the progressive loss of dopaminergic [neurons](/entities/neurons) in the substantia nigra pars compacta, leading to decreased dopamine production and the classic motor symptoms of tremor, bradykinesia, rigidity, and postural instability. Current treatments including levodopa, dopamine agonists, and deep brain stimulation provide symptomatic relief but do not halt disease progression. iPSC therapy offers a fundamentally different approach by replacing lost neurons[@barker2017].

Mechanism of Action

Dopaminergic Neuron Replacement

iPSC therapy for Parkinson's disease works through several interconnected mechanisms:

Cell Transplantation: iPSCs are differentiated into dopaminergic progenitor cells and transplanted into the striatum or substantia nigra of PD patients

Neuronal Maturation: Transplanted progenitors mature into functional dopaminergic neurons over time

Neural Circuit Integration: New neurons extend axons and form synaptic connections with host neurons in the striatum

Dopamine Production: Mature dopaminergic neurons produce and release dopamine, restoring neurotransmitter levels

Trophic Support: Transplanted cells may secrete neurotrophic factors that support remaining endogenous neurons[@parmar2020]

Why Dopaminergic Neurons?

The substantia nigra dopaminergic neurons are particularly vulnerable in Parkinson's disease due to several factors:

High metabolic demands from sustained pacemaking activity
Complex neuronal morphology with extensive axonal arbors
Mitochondrial dysfunction leading to oxidative stress
Exposure to neuromelanin and iron accumulation

Replacing these specific neurons addresses the root cause of dopamine deficiency rather than just treating symptoms[@kalia2015].

Clinical Programs

BlueRock Therapeutics DA01

BlueRock Therapeutics, a biotechnology company focused on engineered cell therapies, developed DA01 (bemdaneprocel), an iPSC-derived dopaminergic neuron therapy for Parkinson's disease[@bluerock2023].

Clinical Trial Results:

The Phase 1 trial (NCT04802733) was a first-in-human, open-label study evaluating the safety and tolerability of DA01 in patients with advanced Parkinson's disease. The trial enrolled patients who were 50-75 years old with a minimum of 5 years of PD diagnosis and Hoehn & Yahr stage 2.5-3 in the off medication state[@clinicaltrialsgov2021].

Key findings included:

No serious adverse events related to the cell transplant
Evidence of survival and engraftment of transplanted cells
Some patients showed improvements in motor function scores
Longer-term follow-up studies are ongoing

BlueRock was acquired by Bayer in 2023 and later became part of Bayer's cell therapy pipeline, continuing development under the bemdaneprocel brand name.

Kyoto University iPSC Trials

The Kyoto University iPSC therapy program, led by Dr. Jun Takahashi and colleagues at the Center for iPS Cell Research and Application (CiRA), has been at the forefront of iPSC therapy for Parkinson's disease[@cyranoski2018].

Trial Design:

The Kyoto University trials have progressed through several phases:

Preclinical Studies: Demonstrated safety and efficacy in primate models of Parkinson's disease

Phase 1 (2018-2020): First-in-human trial using autologous iPSCs in 7 patients

Phase 1/2 (2021-present): Expanding to allogeneic iPSC therapy with improved protocols

Key Innovations:

Development of a robust differentiation protocol for producing high-purity dopaminergic neurons
Strategies to minimize tumor risk through cell purification
Immunosuppression protocols for allogeneic transplants
MRI-guided surgical delivery optimization

Other Notable Programs

iRegene Therapeutics - NouvNeu001:

NCT06167681: Phase I/II trial in China
Human dopaminergic progenitor cells
40 participants enrolled
Recruiting in Beijing and Wuhan[@clinicaltrialsgov2024]

Aspen Neuroscience:

Autologous iPSC-derived dopaminergic neurons
Preclinical development
Focus on personalized medicine approach

Novo Nordisk:

hESC-derived dopaminergic neurons
Preclinical and early clinical development
Focus on scalable manufacturing

Cell Manufacturing

iPSC Derivation and Expansion

The manufacturing process for iPSC-derived dopaminergic neurons involves several critical steps:

Somatic Cell Collection: Patient skin fibroblasts or blood cells are collected

Reprogramming: Cells are reprogrammed using integration-free methods (episomal vectors, mRNA, or sendai virus) to generate iPSCs

Expansion: iPSCs are expanded in culture to generate sufficient cell numbers

Quality Control: Cells are tested for pluripotency, genetic stability, and absence of pathogens

Dopaminergic Different Protocol

Directed differentiation involves staged specification:

Critical factors include:

Optimized growth factor combinations (SHH, FGF8, BDNF, GDNF)
Matrix composition for 2D or 3D culture
Oxygen tension during differentiation
Metabolic selection to eliminate undifferentiated cells[@kriks2011]

Manufacturing Challenges

Scalability: Producing billions of clinical-grade cells consistently remains challenging. Large-scale bioreactor systems are being developed to meet commercial production needs.

Quality Control: Each batch requires extensive testing:

Identity (STR profiling, marker expression)
Purity (flow cytometry for dopaminergic markers)
Potency (functional assays in vitro or in animal models)
Safety (teratoma formation, tumorigenicity, sterility)
Genetic stability (karyotyping, SNP arrays)

Cost: Autologous iPSC therapy is extremely expensive ($500,000-$1,000,000 per patient) due to the individualized manufacturing process. Allogeneic off-the-shelf products could significantly reduce costs.

Regulatory: Manufacturing must comply with current good manufacturing practice (cGMP) requirements and receive regulatory approval from FDA, EMA, PMDA, or other agencies[@taylor2022].

Surgical Delivery

Stereotactic Neurosurgery

iPSC-derived dopaminergic neurons are delivered directly into the brain using stereotactic neurosurgery, a precise, minimally invasive technique.

Planning:

High-resolution MRI for target identification
Computational trajectory planning
Avoidance of blood vessels and critical structures

Targets:

Striatum (putamen): Primary target for dopamine restoration
Substantia nigra: Direct replacement of lost neurons
Combined approach: Some protocols target both regions

Procedure:

Patient is placed in a stereotactic frame (or frameless navigation used)

Burr hole made in the skull

Cannula inserted along pre-planned trajectory

Cells are injected at multiple depths along the trajectory

Careful hemostasis and closure

Delivery Challenges

Cell Survival: Only a fraction of transplanted cells survive. Strategies to improve survival include:

Optimized cell concentration and delivery volume
Pre-conditioning cells to hypoxia
Co-transplantation with supportive cells or biomaterials
Trophic factor supplementation post-transplant

Migration: Cells need to migrate appropriately within the brain. Research shows dopaminergic progenitors can migrate to appropriate brain regions when delivered to suitable sites.

Immune Response: Even with immunosuppression, the brain's immune response can affect cell survival. The [blood-brain barrier](/entities/blood-brain-barrier) creates an immunoprivileged environment, but not complete immune tolerance.

Functional Integration: Ensuring proper synaptic integration with existing neural circuits remains challenging. Animal studies show functional connections can form, but human data is still being collected[@bjorklund2002].

Efficacy Data

Clinical Outcomes

While comprehensive long-term data is still being collected, early results from clinical trials show:

Motor Function:

Some patients show improvements in OFF-medication Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores
Effects appear to develop gradually over months as cells mature and integrate
Durability beyond 2-3 years remains to be established

Dopamine Imaging:

[¹²³I]FP-CIT SPECT imaging shows increased dopamine transporter binding in some patients
PET studies with [¹⁸F]FDOPA show increased dopamine synthesis capacity
These objective measures support cell survival and function

Clinical Ratings:

Hoehn & Yahr staging has shown improvement in some patients
Quality of life measures (PDQ-39) show trends toward improvement
Daily on/off time fluctuations may be reduced

Biomarkers and Monitoring

Several approaches are used to monitor transplant function:

Limitations of Current Data

Small patient numbers in early trials
Limited long-term follow-up (most trials <5 years)
Variable response across patients
Need for randomized, controlled trials to establish efficacy

Challenges and Considerations

Safety Concerns

Tumor Formation: Undifferentiated iPSCs can form teratomas or, theoretically, malignant tumors. Rigorous purification protocols and quality control testing are essential.

Immune Rejection: Even autologous iPSCs may have immunogenic differences due to genetic variants or epigenetic changes. Allogeneic transplants require immunosuppression.

Off-target Effects: Cells may differentiate into unintended cell types or migrate to inappropriate brain regions.

Ethical Considerations

iPSC derivation from patient cells requires informed consent
Embryonic stem cell-derived products have additional ethical concerns
Equity in access to expensive personalized therapies

Future Directions

Combination Therapies:

iPSC therapy combined with gene therapy for enhanced function
Adjunctive small molecule or antibody treatments
Device-assisted delivery (e.g., encapsulated cell biodelivery)

Gene Editing:

Correcting disease-causing mutations in patient-derived iPSCs
Engineering cells for enhanced survival or function
Creating universal donor iPSC lines

3D Bioprinting:

Pre-formed tissue constructs for transplantation
Improved spatial control over cell placement
Vascularized constructs for better survival

Cross-Links

[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Dopamine](/entities/dopamine)
[Substantia Nigra](/brain-regions/substantia-nigra)
[Cell Therapy for Neurodegenerative Diseases](/therapeutics/cell-therapy-neurodegeneration)
[iPSC-Derived Dopaminergic Neurons](/cell-types/ipsc-derived-dopaminergic-neurons)
[BlueRock Therapeutics](/companies/bluerock-therapeutics)
[Kyoto University](/institutions/kyoto-university)
[NouvNeu001 Cell Therapy for Parkinson's Disease](/clinical-trials/nouvneu001-pd)
[LRRK2 Gene Therapy](/therapeutics/lrrk2-gene-therapy-parkinsons)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Takahashi, J. (2023). iPS cell-based therapy for Parkinson's disease: A clinical trial update (2023)](https://doi.org/10.1016/j.stemcr.2022.12.001)

[Barker, R. A., et al., (2017). Getting ready for prime time: Cell-based therapies for Parkinson's disease (2017)](https://doi.org/10.1038/nrneurol.2017.138)

[Parmar, M., et al, (2020) (2020)](https://doi.org/10.1016/bs.pbr.2020.01.017)

[Unknown, Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease (2015)](https://doi.org/10.1016/S0140-6736(14)

Unknown, BlueRock Therapeutics. (2023). Pipeline: DA01 for Parkinson's disease (2023)

Unknown, ClinicalTrials.gov. (2021). Study of DA01 in Parkinson's Disease. NCT04802733 (2021)

[Unknown, Cyranoski, D. (2018). Japan's first trial of stem cell therapy for Parkinson's disease (2018)](https://doi.org/10.1038/d41586-018-05720-9)

Unknown, ClinicalTrials.gov. (2024). NouvNeu001 in Parkinson's Disease. NCT06167681 (2024)

[Kriks, S., et al, (2011) (2011)](https://doi.org/10.1038/nature10648)

[Taylor, J. P., et al., (2022). Stem cells as a therapeutic approach to Parkinson's disease: Progress and challenges (2022)](https://doi.org/10.1016/j.ymthe.2021.10.015)

[Bjorklund, L. M., et al., (2002). Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model (2002)](https://doi.org/10.1073/pnas.022438099)

Therapeutic Mechanism

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving iPSC Therapy for Parkinson's Disease discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-ipsc-therapy-parkinsons-disease

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ipsc-therapy-parkinsons-disease
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6c819c460ec1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ipsc-therapy-parkinsons-disease'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

163

Outgoing

230

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

iPSC Therapy for Parkinson's Disease

iPSC Therapy for Parkinson's Disease

Overview

iPSC Therapy for Parkinson's Disease

Overview

Mechanism of Action

Dopaminergic Neuron Replacement

Why Dopaminergic Neurons?

Clinical Programs

BlueRock Therapeutics DA01

Kyoto University iPSC Trials

Other Notable Programs

Cell Manufacturing

iPSC Derivation and Expansion

Dopaminergic Different Protocol

Manufacturing Challenges

Surgical Delivery

Stereotactic Neurosurgery

Delivery Challenges

Efficacy Data

Clinical Outcomes

Biomarkers and Monitoring

Limitations of Current Data

Challenges and Considerations

Safety Concerns

Ethical Considerations

Future Directions

Cross-Links

See Also

External Links

References

Therapeutic Mechanism

Pathway Diagram

💬 Discussion